Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cardiovascular Diabetology
Published in: Cardiovascular Diabetology 1/2003

Open Access 01-12-2003 | Review

Influence of diabetes mellitus on heart failure risk and outcome

Authors: Christophe Bauters, Nicolas Lamblin, Eugène P Mc Fadden, Eric Van Belle, Alain Millaire, Pascal de Groote

Published in: Cardiovascular Diabetology | Issue 1/2003

Login to get access

Abstract

Our aim is to summarize and discuss the recent literature linking diabetes mellitus with heart failure, and to address the issue of the optimal treatment for diabetic patients with heart failure.

The studies linking diabetes mellitus (DM) with heart failure (HF)

The prevalence of diabetes mellitus in heart failure populations is close to 20% compared with 4 to 6% in control populations. Epidemiological studies have demonstrated an increased risk of heart failure in diabetics; moreover, in diabetic populations, poor glycemic control has been associated with an increased risk of heart failure. Various mechanisms may link diabetes mellitus to heart failure: firstly, associated comorbidities such as hypertension may play a role; secondly, diabetes accelerates the development of coronary atherosclerosis; thirdly, experimental and clinical studies support the existence of a specific diabetic cardiomyopathy related to microangiopathy, metabolic factors or myocardial fibrosis. Subgroup analyses of randomized trials demonstrate that diabetes is also an important prognostic factor in heart failure. In addition, it has been suggested that the deleterious impact of diabetes may be especially marked in patients with ischemic cardiomyopathy.

Treatment of heart failure in diabetic patients

The knowledge of the diabetic status may help to define the optimal therapeutic strategy for heart failure patients. Cornerstone treatments such as ACE inhibitors or beta-blockers appear to be uniformly beneficial in diabetic and non diabetic populations. However, in ischemic cardiomyopathy, the choice of the revascularization technique may differ according to diabetic status. Finally, clinical studies are needed to determine whether improved metabolic control might favorably influence the outcome of diabetic heart failure patients.
Appendix
Available only for authorised users
Literature
1.
American-Heart-Association: 1999 Heart and Stroke Statistical Update. In: Book 1999 Heart and Stroke Statistical Update (Editor ed.). 1998, City: American Heart Association
2.
Rich MW: Epidemiology, pathophysiology, and etiology of congestive heart failure in older adults. J Am Geriatr Soc. 1997, 45: 974-968.
3.
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999, 353: 9-13.
4.
Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Ryden L, Thygesen K, Uretsky BF: Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation. 1999, 100: 2312-2318.CrossRefPubMed
5.
Croft JB, Giles WH, Pollard RA, Keenan NL, Casper ML, Anda RF: Heart failure survival among older adults in the United States: a poor prognosis for an emerging epidemic in the Medicare population. Arch Intern Med. 1999, 159: 505-510.CrossRefPubMed
6.
Zannad F, Braincon S, Juilliere Y, Mertes PM, Villemot JP, Alla F, Virion JM: Incidence, clinical and etiologic features, and outcomes of advanced chronic heart failure: the EPICAL Study. Epidemiologie de l'Insuffisance Cardiaque Avancee en Lorraine. J Am Coll Cardiol. 1999, 33: 734-742.CrossRefPubMed
7.
Levit KR, Lazenby HC, Cowan CA, Letsch SW: National health expenditures, 1990. Health Care Financ Rev. 1991, 13: 29-54.PubMedCentralPubMed
8.
O'Connell JB, Bristow MR: Economic impact of heart failure in the United States: time for a different approach. J Heart Lung Transplant. 1994, 13: S107-112.PubMed
9.
10.
King H, Aubert RE, Herman WH: Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998, 21: 1414-1431.CrossRefPubMed
11.
Kannel WB, McGee DL: Diabetes and cardiovascular disease. The Framingham study. Jama. 1979, 241: 2035-2038.CrossRefPubMed
12.
Dorman JS, Laporte RE, Kuller LH, Cruickshanks KJ, Orchard TJ, Wagener DK, Becker DJ, Cavender DE, Drash AL: The Pittsburgh insulin-dependent diabetes mellitus (IDDM) morbidity and mortality study. Mortality results. Diabetes. 1984, 33: 271-276.CrossRefPubMed
13.
Krolewski AS, Warram JH, Rand LI, Kahn CR: Epidemiologic approach to the etiology of type I diabetes mellitus and its complications. N Engl J Med. 1987, 317: 1390-1398.CrossRefPubMed
14.
Lloyd CE, Kuller LH, Ellis D, Becker DJ, Wing RR, Orchard TJ: Coronary artery disease in IDDM. Gender differences in risk factors but not risk. Arterioscler Thromb Vasc Biol. 1996, 16: 720-726.CrossRefPubMed
15.
Tuomilehto J, Borch-Johnsen K, Molarius A, Forsen T, Rastenyte D, Sarti C, Reunanen A: Incidence of cardiovascular disease in Type 1 (insulin-dependent) diabetic subjects with and without diabetic nephropathy in Finland. Diabetologia. 1998, 41: 784-790.CrossRefPubMed
16.
Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M: A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991, 325: 303-310.CrossRefPubMed
17.
Shindler DM, Kostis JB, Yusuf S, Quinones MA, Pitt B, Stewart D, Pinkett T, Ghali JK, Wilson AC: Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol. 1996, 77: 1017-1020.CrossRefPubMed
18.
Ryden L, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Packer M, Poole-Wilson PA: Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. Eur Heart J. 2000, 21: 1967-1978.CrossRefPubMed
19.
Solang L, Malmberg K, Ryden L: Diabetes mellitus and congestive heart failure. Further knowledge needed. Eur Heart J. 1999, 20: 789-795.CrossRefPubMed
20.
Swan JW, Anker SD, Walton C, Godsland IF, Clark AL, Leyva F, Stevenson JC, Coats AJ: Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J Am Coll Cardiol. 1997, 30: 527-532.CrossRefPubMed
21.
Tenenbaum A, Motro M, Fisman EZ, Leor J, Boyko V, Mandelzweig L, Behar S: Status of glucose metabolism in patients with heart failure secondary to coronary artery disease. Am J Cardiol. 2002, 90: 529-532.CrossRefPubMed
22.
Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Bmj. 2000, 321: 405-412.PubMedCentralCrossRefPubMed
23.
Iribarren C, Karter AJ, Go AS, Ferrara A, Liu JY, Sidney S, Selby JV: Glycemic control and heart failure among adult patients with diabetes. Circulation. 2001, 103: 2668-2673.CrossRefPubMed
24.
Amato L, Paolisso G, Cacciatore F, Ferrara N, Ferrara P, Canonico S, Varricchio M, Rengo F: Congestive heart failure predicts the development of non-insulin-dependent diabetes mellitus in the elderly. The Osservatorio Geriatrico Regione Campania Group. Diabetes Metab. 1997, 23: 213-218.PubMed
25.
Martens FM, Visseren FL, Lemay J, de Koning EJ, Rabelink TJ: Metabolic and additional vascular effects of thiazolidinediones. Drugs. 2002, 62: 1463-1480.CrossRefPubMed
26.
Kannel WB, McGee DL: Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care. 1979, 2: 120-126.CrossRefPubMed
27.
Dries DL, Sweitzer NK, Drazner MH, Stevenson LW, Gersh BJ: Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction. J Am Coll Cardiol. 2001, 38: 421-428.CrossRefPubMed
28.
Gheorghiade M, Bonow RO: Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation. 1998, 97: 282-289.CrossRefPubMed
29.
Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998, 339: 229-334.CrossRefPubMed
30.
Nitenberg A, Valensi P, Sachs R, Dali M, Aptecar E, Attali JR: Impairment of coronary vascular reserve and ACh-induced coronary vasodilation in diabetic patients with angiographically normal coronary arteries and normal left ventricular systolic function. Diabetes. 1993, 42: 1017-25.CrossRefPubMed
31.
Ceriello A: Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects. Diabetologia. 1993, 36: 1119-25.CrossRefPubMed
32.
Nordt TK, Sawa H, Fujii S, Sobel BE: Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo. Circulation. 1995, 91: 764-770.CrossRefPubMed
33.
Sobel BE, Woodcock-Mitchell J, Schneider DJ, Holt RE, Marutsuka K, Gold H: Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence. Circulation. 1998, 97: 2213-2221.CrossRefPubMed
34.
Zareba W, Pancio G, Moss AJ, Kalaria VG, Marder VJ, Weiss HJ, Watelet LF, Sparks CE: Increased level of von Willebrand factor is significantly and independently associated with diabetes in postinfarction patients. THROMBO Investigators. Thromb Haemost. 2001, 86: 791-799.PubMed
35.
Knobler H, Savion N, Shenkman B, Kotev-Emeth S, Varon D: Shear-induced platelet adhesion and aggregation on subendothelium are increased in diabetic patients. Thromb Res. 1998, 90: 181-190.CrossRefPubMed
36.
Shechter M, Merz CN, Paul-Labrador MJ, Kaul S: Blood glucose and platelet-dependent thrombosis in patients with coronary artery disease. J Am Coll Cardiol. 2000, 35: 300-307.CrossRefPubMed
37.
Jilma B, Fasching P, Ruthner C, Rumplmayr A, Ruzicka S, Kapiotis S, Wagner OF, Eichler HG: Elevated circulating P-selectin in insulin dependent diabetes mellitus. Thromb Haemost. 1996, 76: 328-332.PubMed
38.
Tschoepe D, Roesen P, Kaufmann L, Schauseil S, Kehrel B, Ostermann H, Gries FA: Evidence for abnormal platelet glycoprotein expression in diabetes mellitus. Eur J Clin Invest. 1990, 20: 166-170.CrossRefPubMed
39.
40.
Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A: New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol. 1972, 30: 595-602.CrossRefPubMed
41.
Factor SM, Okun EM, Minase T: Capillary microaneurysms in the human diabetic heart. N Engl J Med. 1980, 302: 384-388.CrossRefPubMed
42.
Gherasim L, Tasca C, Havriliuc C, Vasilescu C: A morphological quantitative study of small vessels in diabetic cardiomyopathy. Morphol Embryol (Bucur). 1985, 31: 191-195.
43.
Yarom R, Zirkin H, Stammler G, Rose AG: Human coronary microvessels in diabetes and ischaemia. Morphometric study of autopsy material. J Pathol. 1992, 166: 265-270.CrossRefPubMed
44.
Nitenberg A, Paycha F, Ledoux S, Sachs R, Attali JR, Valensi P: Coronary artery responses to physiological stimuli are improved by deferoxamine but not by L-arginine in non-insulin-dependent diabetic patients with angiographically normal coronary arteries and no other risk factors. Circulation. 1998, 97: 736-743.CrossRefPubMed
45.
Nahser PJ, Brown RE, Oskarsson H, Winniford MD, Rossen JD: Maximal coronary flow reserve and metabolic coronary vasodilation in patients with diabetes mellitus. Circulation. 1995, 91: 635-640.CrossRefPubMed
46.
Rodrigues B, McNeill JH: The diabetic heart: metabolic causes for the development of a cardiomyopathy. Cardiovasc Res. 1992, 26: 913-922.CrossRefPubMed
47.
Rodrigues B, Cam MC, McNeill JH: Metabolic disturbances in diabetic cardiomyopathy. Mol Cell Biochem. 1998, 180: 53-57.CrossRefPubMed
48.
Lopaschuk GD: Abnormal mechanical function in diabetes: relationship to altered myocardial carbohydrate/lipid metabolism. Coron Artery Dis. 1996, 7: 116-123.CrossRefPubMed
49.
Regan TJ, Wu CF, Yeh CK, Oldewurtel HA, Haider B: Myocardial composition and function in diabetes. The effects of chronic insulin use. Circ Res. 1981, 49: 1268-1277.CrossRefPubMed
50.
51.
Brownlee M, Cerami A, Vlassara H: Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med. 1988, 318: 1315-1321.CrossRefPubMed
52.
Avendano GF, Agarwal RK, Bashey RI, Lyons MM, Soni BJ, Jyothirmayi GN, Regan TJ: Effects of glucose intolerance on myocardial function and collagen-linked glycation. Diabetes. 1999, 48: 1443-1447.CrossRefPubMed
53.
Asif M, Egan J, Vasan S, Jyothirmayi GN, Masurekar MR, Lopez S, Williams C, Torres RL, Wagle D, Ulrich P: An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness. Proc Natl Acad Sci U S A. 2000, 97: 2809-2813.PubMedCentralCrossRefPubMed
54.
Takahashi N, Iwasaka T, Sugiura T, Hasegawa T, Tarumi N, Kimura Y, Kurihara S, Onoyama H, Inada M: Left ventricular regional function after acute anterior myocardial infarction in diabetic patients. Diabetes Care. 1989, 12: 630-635.CrossRefPubMed
55.
Iwasaka T, Takahashi N, Nakamura S, Sugiura T, Tarumi N, Kimura Y, Okubo N, Taniguchi H, Matsui Y, Inada M: Residual left ventricular pump function after acute myocardial infarction in NIDDM patients. Diabetes Care. 1992, 15: 1522-1526.CrossRefPubMed
56.
Woodfield SL, Lundergan CF, Reiner JS, Greenhouse SW, Thompson MA, Rohrbeck SC, Deychak Y, Simoons ML, Califf RM, Topol EJ: Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience. J Am Coll Cardiol. 1996, 28: 1661-1669.CrossRefPubMed
57.
van Hoeven KH, Factor SM: A comparison of the pathological spectrum of hypertensive, diabetic, and hypertensive-diabetic heart disease. Circulation. 1990, 82: 848-855.CrossRefPubMed
58.
Mancini DM, Eisen H, Kussmaul W, Mull R, Edmunds LH, Wilson JR: Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation. 1991, 83: 778-786.CrossRefPubMed
59.
Griffin BP, Shah PK, Ferguson J, Rubin SA: Incremental prognostic value of exercise hemodynamic variables in chronic congestive heart failure secondary to coronary artery disease or to dilated cardiomyopathy. Am J Cardiol. 1991, 67: 848-853.CrossRefPubMed
60.
Anguita M, Arizon JM, Bueno G, Latre JM, Sancho M, Torres F, Gimenez D, Concha M, Valles F: Clinical and hemodynamic predictors of survival in patients aged <65 years with severe congestive heart failure secondary to ischemic or nonischemic dilated cardiomyopathy. Am J Cardiol. 1993, 72: 413-417.CrossRefPubMed
61.
Cohn JN, Johnson GR, Shabetai R, Loeb H, Tristani F, Rector T, Smith R, Fletcher R: Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. The V-HeFT VA Cooperative Studies Group. Circulation. 1993, 87: VI5-16.PubMed
62.
de Groote P, Millaire A, Foucher-Hossein C, Nugue O, Marchandise X, Ducloux G, Lablanche JM: Right ventricular ejection fraction is an independent predictor of survival in patients with moderate heart failure. J Am Coll Cardiol. 1998, 32: 948-954.CrossRefPubMed
63.
Follath F, Cleland JG, Klein W, Murphy R: Etiology and response to drug treatment in heart failure. J Am Coll Cardiol. 1998, 32: 1167-1172.CrossRefPubMed
64.
Burke AP, Kolodgie FD, Farb A, Weber DK, Malcom GT, Smialek J, Virmani R: Healed plaque ruptures and sudden coronary death: evidence that subclinical rupture has a role in plaque progression. Circulation. 2001, 103: 934-940.CrossRefPubMed
65.
Uretsky BF, Thygesen K, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Packer M, Poole-Wilson PA, Ryden L: Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation. 2000, 102: 611-616.CrossRefPubMed
66.
Hearse DJ, Stewart DA, Chain EB: Diabetes and the survival and recovery of the anoxic myocardium. J Mol Cell Cardiol. 1975, 7: 397-415.CrossRefPubMed
67.
Ingebretsen CG, Moreau P, Hawelu-Johnson C, Ingebretsen WR: Performance of diabetic rat hearts: effects of anoxia and increased work. Am J Physiol. 1980, 239: H614-20.PubMed
68.
Mokuda O, Sakamoto Y, Ikeda T, Mashiba H: Effects of anoxia and low free fatty acid on myocardial energy metabolism in streptozotocin-diabetic rats. Ann Nutr Metab. 1990, 34: 259-265.CrossRefPubMed
69.
Savabi F, Kirsch A: Altered functional activity and anoxic tolerance in diabetic rat isolated atria. Arch Biochem Biophys. 1990, 279: 183-187.CrossRefPubMed
70.
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med. 1991, 325: 293-302.
71.
Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med. 1992, 327: 685-691.
72.
Maggioni AP, Anand I, Gottlieb SO, Latini R, Tognoni G, Cohn JN: Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol. 2002, 40: 1414-1421.CrossRefPubMed
73.
Erdmann E, Lechat P, Verkenne P, Wiemann H: Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. Eur J Heart Fail. 2001, 3: 469-479.CrossRefPubMed
74.
Dries DL, Domanski MJ, Waclawiw MA, Gersh BJ: Effect of antithrombotic therapy on risk of sudden coronary death in patients with congestive heart failure. Am J Cardiol. 1997, 79: 909-913.CrossRefPubMed
75.
Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996, 335: 1001-1009.CrossRefPubMed
76.
Kjekshus J, Pedersen TR, Olsson AG, Faergeman O, Pyorala K: The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail. 1997, 3: 249-254.CrossRefPubMed
77.
Collaborative overview of randomised trials of antiplatelet therapy – I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. Bmj. 1994, 308: 81-106.
78.
Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 1997, 20: 614-620.CrossRefPubMed
79.
80.
Alderman EL, Fisher LD, Litwin P, Kaiser GC, Myers WO, Maynard C, Levine F, Schloss M: Results of coronary artery surgery in patients with poor left ventricular function (CASS). Circulation. 1983, 68: 785-795.CrossRefPubMed
81.
Pigott JD, Kouchoukos NT, Oberman A, Cutter GR: Late results of surgical and medical therapy for patients with coronary artery disease and depressed left ventricular function. J Am Coll Cardiol. 1985, 5: 1036-1045.CrossRefPubMed
82.
Bounous EP, Mark DB, Pollock BG, Hlatky MA, Harrell FE, Lee KL, Rankin JS, Wechsler AS, Pryor DB, Califf RM: Surgical survival benefits for coronary disease patients with left ventricular dysfunction. Circulation. 1988, 78: 1151-1157.
83.
Elefteriades JA, Tolis G, Levi E, Mills LK, Zaret BL: Coronary artery bypass grafting in severe left ventricular dysfunction: excellent survival with improved ejection fraction and functional state. J Am Coll Cardiol. 1993, 22: 1411-1417.CrossRefPubMed
84.
Baker DW, Jones R, Hodges J, Massie BM, Konstam MA, Rose EA: Management of heart failure. III. The role of revascularization in the treatment of patients with moderate or severe left ventricular systolic dysfunction. Jama. 1994, 272: 1528-34.CrossRefPubMed
85.
Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI). Circulation. 1997, 96: 1761-9.
86.
O'Neill WW: Multivessel balloon angioplasty should be abandoned in diabetic patients!. J Am Coll Cardiol. 1998, 31: 20-2.PubMed
87.
Weintraub WS, Stein B, Kosinski A, Douglas JS, Ghazzal ZM, Jones EL, Morris DC, Guyton RA, Craver JM, King SB: Outcome of coronary bypass surgery versus coronary angioplasty in diabetic patients with multivessel coronary artery disease. J Am Coll Cardiol. 1998, 31: 10-19.CrossRefPubMed
88.
Detre KM, Guo P, Holubkov R, Califf RM, Sopko G, Bach R, Brooks MM, Bourassa MG, Shemin RJ, Rosen AD: Coronary revascularization in diabetic patients: a comparison of the randomized and observational components of the Bypass Angioplasty Revascularization Investigation (BARI). Circulation. 1999, 99: 633-640.CrossRefPubMed
89.
Kuntz RE: Importance of considering atherosclerosis progression when choosing a coronary revascularization strategy: the diabetes-percutaneous transluminal coronary angioplasty dilemma. Circulation. 1999, 99: 847-851.CrossRefPubMed
90.
Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status. J Am Coll Cardiol. 2000, 35: 1122-1129.
91.
Van Belle E, Bauters C, Hubert E, Bodart JC, Abolmaali K, Meurice T, McFadden EP, Lablanche JM, Bertrand ME: Restenosis rates in diabetic patients: a comparison of coronary stenting and balloon angioplasty in native coronary vessels. Circulation. 1997, 96: 1454-1460.CrossRefPubMed
92.
Elezi S, Kastrati A, Pache J, Wehinger A, Hadamitzky M, Dirschinger J, Neumann FJ, Schomig A: Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol. 1998, 32: 1866-1873.CrossRefPubMed
93.
Bhatt DL, Marso SP, Lincoff AM, Wolski KE, Ellis SG, Topol EJ: Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol. 2000, 35: 922-928.CrossRefPubMed
94.
Topol EJ, Mark DB, Lincoff AM, Cohen E, Burton J, Kleiman N, Talley D, Sapp S, Booth J, Cabot CF: Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet. 1999, 354: 2019-2024.CrossRefPubMed
95.
Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G: A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002, 346: 1773-1780.CrossRefPubMed
96.
Bibra H, Hansen A, Dounis V, Bystedt T, malmberg K, Ryden L: Diastolic myocardial function and myocardial microvasculature reserve improve with intense insulin treatment in type 2 diabetic patients. Circulation. 2001, 104 (Suppl II): 369.
97.
The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care. 2002, 25: 2165-2171.
98.
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002, 360: 7-22.
99.
Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000, 342: 145-153.CrossRefPubMed
100.
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. Bmj. 1998, 317: 703-713.
Metadata
Title
Influence of diabetes mellitus on heart failure risk and outcome
Authors
Christophe Bauters
Nicolas Lamblin
Eugène P Mc Fadden
Eric Van Belle
Alain Millaire
Pascal de Groote
Publication date
01-12-2003
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2003
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/1475-2840-2-1

Other articles of this Issue 1/2003

Cardiovascular Diabetology 1/2003 Go to the issue

Review

Metabolic syndrome and type 2 diabetes mellitus: focus on peroxisome proliferator activated receptors (PPAR)

Original investigation

The insertion/deletion variation in the α2B-adrenoceptor does not seem to modify the risk for acute myocardial infarction, but may modify the risk for hypertension in sib-pairs from families with type 2 diabetes

Hypothesis

Is type 2 diabetes mellitus a vascular disease (atheroscleropathy) with hyperglycemia a late manifestation? The role of NOS, NO, and redox stress.

Original investigation

Usefulness of electronic databases for the detection of unrecognized diabetic patients

Original investigation

Silent myocardial infarction in women with impaired glucose tolerance: The Northern Sweden MONICA study

Original investigation

Monocyte matrix metalloproteinase production in Type 2 diabetes and controls – a cross sectional study

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits